mTOR / IGF-1 — A Sardine Protocol Dossier

TL;DR

mTOR / IGF-1 is the part of the longevity-adjacent fasting literature where the gap between rodent evidence (substantial) and human evidence (much more modest) is largest. Lifespan extension by mTOR inhibition (rapamycin) and protein restriction is robust in model organisms; the human translation is highly nuanced. The clean human data for IGF-1 modulation comes from sustained protein-restricted CR ¹, NHANES protein-mortality cohort analysis ², and structured fasting-mimicking protocols ³. A sardine fast does not produce sustained IGF-1 suppression because dietary protein during cycles supplies leucine and amino acid substrate that maintains IGF-1 baseline between cycles. What a sardine fast does engage is acute cycle-window mTORC1 suppression, which is mechanistically interesting but not equivalent to the chronic-suppression mechanism that drives rodent lifespan extension. Anyone selling a monthly 5-day cycle as a "longevity protocol via mTOR / IGF-1" is overselling. This dossier walks through what the evidence does and doesn't support.

What we mean by mTOR and IGF-1

mTOR (mechanistic target of rapamycin) is a serine/threonine kinase that integrates nutrient, energy, and growth-factor signals to regulate cell growth, protein synthesis, and metabolism. mTOR exists in two structurally distinct complexes:

• mTORC1 — activated by amino acids (especially branched-chain amino acids, particularly leucine), insulin and IGF-1 signaling, and high cellular energy charge. Drives protein synthesis, ribosomal biogenesis, lipogenesis. Suppresses autophagy. The rapamycin-sensitive complex.
• mTORC2 — regulates Akt phosphorylation and cytoskeletal dynamics. Less prominent in the longevity-fasting story.

The molecular biology is comprehensively reviewed in Saxton & Sabatini 2017. The relevant point for fasting biology: mTORC1 inhibition releases the autophagy program (Mizushima 2008, Levine & Kroemer 2008) and suppresses anabolic protein synthesis. Repeated mTORC1 inhibition (via rapamycin pharmacologically, or via protein-restricted dietary patterns nutritionally) extends lifespan in every model organism studied, with the cleanest mammalian evidence from rapamycin-mouse-lifespan trials.

IGF-1 (insulin-like growth factor 1) is a peptide hormone primarily produced by liver in response to growth-hormone signaling. IGF-1 binds the IGF-1 receptor on target tissues and activates the PI3K-Akt-mTOR pathway. Circulating IGF-1 is a major mediator of growth and tissue maintenance and is partially under dietary control — protein intake (especially animal protein) is the strongest dietary driver of IGF-1 elevation in adult humans.

The longevity hypothesis links these two. Lower mTOR signaling and lower IGF-1 are associated with extended lifespan in every model organism studied (yeast, worms, flies, mice). The cleanest mammalian evidence is rapamycin extending mouse lifespan in well-controlled studies; daf-2 (IGF-1-receptor) mutations doubling C. elegans lifespan; protein-restriction extending lifespan in mice across multiple labs. The translation to humans is where the discourse outruns the evidence.

What the evidence says (the public preview cuts here)

The Fontana 2008 finding — protein restriction, not calorie restriction, drives IGF-1 reduction:

Fontana 2008 is the foundational human study. Fontana compared three groups:

1. Long-term calorie-restriction practitioners (CR with adequate protein, multi-year duration).
2. Long-term endurance athletes (matched body composition, normal protein intake).
3. Western controls (typical Western diet).

Key findings:

• The CR group had body composition similar to endurance athletes (low body fat, lean muscle).
• The CR group did not have substantially lower IGF-1 than Western controls.
• Endurance athletes despite very low body fat had unchanged IGF-1 because their protein intake was normal-to-high.
• A subsequent within-subject experiment in CR practitioners showed that adding protein restriction on top of calorie restriction lowered IGF-1 substantially.

The implication reframes the popular longevity discussion. Lifelong CR-with-protein-restriction in humans does lower IGF-1 and may extend healthspan markers; CR alone or short fasts alone — without sustained protein restriction — do not durably modify IGF-1 in the way that drives the rodent lifespan-extension findings.

The Levine-Longo 2014 NHANES analysis:

Levine & Longo 2014 extended the picture with a large NHANES cohort analysis. They reported:

• High protein intake in midlife adults (50–65) was associated with higher all-cause and cancer-related mortality, with an effect size suggestive of a meaningful relative-risk increase at the highest protein intakes.
• The association attenuated or reversed in adults over 65 — the high-protein/mortality association did not hold in older adults, where adequate protein became protective rather than harmful.
• IGF-1 mediated a substantial fraction of the protein-mortality association, with the largest associations in adults whose IGF-1 was elevated.

The interpretation is contested — observational, food-frequency-questionnaire-based, with the usual confounding caveats — but the dose-response direction is consistent with the rodent IGF-1 / mTOR story. The age-modification finding (older adults benefit from more protein, not less) has implications for how the protocol thinks about tier-specific recommendations.

The Brandhorst & Longo 2015 fasting-mimicking-diet trial:

Brandhorst & Longo 2015 tests the structured FMD (5 days/month, very low calorie, low protein, plant-based) over three monthly cycles in midlife adults. Findings:

• Modest reductions in IGF-1, glucose, and other healthspan markers.
• Effect sizes are real but modest — IGF-1 reductions in the 10–20% range during cycles, partially recovering between cycles.
• Body composition shifts (modest weight loss, some lean mass loss alongside fat loss).

This is the most directly applicable human evidence for "monthly 5-day cycles affect mTOR / IGF-1 biology." The FMD is not a sardine fast — the protein content differs substantially. But the cycle pattern and the outcome direction are both relevant for thinking about what a sardine fast might do at the IGF-1 level.

The intermittent-fasting and metabolic-switch literature:

Anton 2018, Mattson 2017, and de Cabo & Mattson 2019 catalog mTOR / IGF-1 modulation among the proposed mechanisms of intermittent fasting's benefits. The reviews are appropriately careful about the rodent-to-human extrapolation. The "metabolic switch" framing places repeated mTOR-suppression cycles in the same conceptual family as repeated ketosis cycles and repeated AMPK activation — proposed cumulative benefits from frequent switching.

The PSMF protein-dose data:

Bistrian 1978 and Contaldo 1980 establish the protein dose used in clinical PSMF (1.2–1.5 g/kg ideal body weight per day). This is the protein range a well-dosed sardine fast operates in. At this protein dose, mTORC1 is partially but not fully suppressed during the cycle — leucine availability is meaningful but not at maintenance fed-state levels.

The βHB-signaling angle:

Newman & Verdin 2014 raises the possibility that β-hydroxybutyrate has direct mTOR-relevant signaling effects through HDAC inhibition. The evidence is largely preclinical. Whether ketosis at sardine-fast levels (1.5–2.5 mmol/L βHB) produces mTOR-relevant signaling in humans beyond the dietary-protein-and-substrate-mediated effects is unstudied.

Reproductive-hormone and women-specific considerations:

Velissariou 2025 PCOS/fertility review and Cienfuegos 2022 address fasting effects on reproductive hormone axes in women. mTOR / IGF-1 biology intersects directly with reproductive-hormone signaling (the GH-IGF-1 axis affects ovarian function, menstrual regularity, and fertility). The takeaway from these reviews: fasting protocols can modulate reproductive-hormone biology in ways that vary by protocol intensity, baseline body composition, and age. Sustained or aggressive cycling in women in the reproductive years requires more careful monitoring than equivalent protocols in men.